While global harmonisation remains the holy grail, the reality is that pharmaceutical companies still face significant challenges navigating regulatory differences. Stefanie Lietsch-Dallwig considers whether changes to the local affiliate model could ease the load. With the rapid evolution of the global regulatory environment, pharmaceutical companies must deal with increasingly complex and often competing demands in…